MLA Diagnostics

medical devices

About

Melanoma is the most deadly form of skin cancer. After diagnosis it is vital to know whether the disease is likely to spread. Prognostic information is important at this stage. Unfortunately current prognostic tools often classify patients as low risk but these patients still progress to metastatic disease and die without getting the treatment they needed. MLA Diagnostics' innovative product is an in vitro diagnostic (IVD) method that is able to determine melanoma patients with low or high metastatic risk. Performed by the pathologist, this test provides more insight on a patients' expected outcome and will enable a different course of treatment (more or less intensive).

Technologies

Outlook Apache Varnish WordPress.org Google Font API reCAPTCHA Mobile Friendly Circle

Keywords

medical equipment manufacturing epigenetics biomarker-based prognostics cancer prognosis clinical validation studies research and development in the physical engineering and life sciences clinical decision support oncology healthcare technology melanoma recurrence prediction biomarker validation b2b molecular assay workflow government non-invasive diagnostic medical diagnostics ly75 methylation biotechnology molecular diagnostics dna methylation biomarkers patient care risk assessment healthcare services melanoma risk assessment personalized medicine clinical workflow integration epigenetic tumor markers

Location

55 Oxfordlaan, Maastricht, Limburg, Netherlands, 6229 EV

Related Companies

Companies in the same industry